Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AIMS: The aim of this systematic review was to explore and evaluate the efficacy of interventions to reduce the prevalence of look-alike, sound-alike (LASA) medication name errors. METHODS: We conducted a systematic review of the literature, searching PubMed, EMBASE, Scopus, and Web of Science up to December 2016, and re-ran the search in February 2020 for later results. We included studies of interventions to reduce LASA errors, and included randomised controlled trials, controlled before-and-after studies, and interrupted time series. Details were registered in Prospero (ID: CRD42016048198). RESULTS: We identified six studies that fulfilled our inclusion criteria. All were conducted in laboratories. Given the diversity in the included studies, we did not conduct a meta-analysis, and instead report the findings narratively. The only intervention explored in RCTs was capitalisation of selected letters ('Tall Man'), for which we found limited efficacy and no consensus. CONCLUSIONS: Tall Man lettering is a marginally effective intervention to reduce LASA errors, with a number of caveats. We suggest that there Tall Man gives rise to a 'quasi-placebo effect', whereby a user derives more benefit from Tall Man lettering if they are aware of its purpose.

Original publication

DOI

10.1111/bcp.14644

Type

Journal article

Journal

Br J Clin Pharmacol

Publication Date

16/11/2020